<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; methodology</title>
	<atom:link href="http://www.tapanray.in/tag/methodology/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Is The New ‘Market Based Pricing’ Model Fundamentally Flawed?</title>
		<link>http://www.tapanray.in/is-the-new-market-based-pricing-model-fundamentally-flawed/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-new-market-based-pricing-model-fundamentally-flawed</link>
		<comments>http://www.tapanray.in/is-the-new-market-based-pricing-model-fundamentally-flawed/#comments</comments>
		<pubDate>Mon, 07 Apr 2014 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[advance]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[CBP]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[crocin]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[flawed]]></category>
		<category><![CDATA[fundamentally]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[MBP]]></category>
		<category><![CDATA[methodology]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[span]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5193</guid>
		<description><![CDATA[After a long wait of close to two decades, when the Drug Price Control Order 2013 (DPCO 2013) followed the National Pharmaceutical Pricing Policy 2012 (NPPP 2012) last year, it appeared that the new pharma price control regime is more &#8230; <a href="http://www.tapanray.in/is-the-new-market-based-pricing-model-fundamentally-flawed/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-new-market-based-pricing-model-fundamentally-flawed/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Drug Price Control Order of India: Is it Directionally Right Improving Access to Medicines?</title>
		<link>http://www.tapanray.in/new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines</link>
		<comments>http://www.tapanray.in/new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines/#comments</comments>
		<pubDate>Mon, 27 May 2013 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2002]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[accuracy]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[benefit]]></category>
		<category><![CDATA[ceiling]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Challenging]]></category>
		<category><![CDATA[CO]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DPCO2013]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Karnataka]]></category>
		<category><![CDATA[litigation]]></category>
		<category><![CDATA[margin]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[methodology]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NLEM 2011]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Order]]></category>
		<category><![CDATA[outsourced]]></category>
		<category><![CDATA[overview]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[retail]]></category>
		<category><![CDATA[Ringside]]></category>
		<category><![CDATA[span]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[view]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2546</guid>
		<description><![CDATA[The last Drug Policy of India was announced in 2002, which was subsequently challenged by a Public Interest Litigation (PIL) in the Karnataka High Court on the ground of being inflationary in nature. The Honorable Court by its order dated &#8230; <a href="http://www.tapanray.in/new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
